Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 10Pancreatic Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 5Stomach Neoplasms 4Sarcoma 4Cholangiocarcinoma 4Ovarian Neoplasms 3Osteosarcoma 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroendocrine Tumor Grade 3 1Neuroectodermal Tumors, Primitive 1NSCLC 1Lymphoma 1

Interventions

Fluorouracil 497Bevacizumab 476Oxaliplatin 449Leucovorin 440Irinotecan 408Cetuximab 317Capecitabine 317pembrolizumab 142Folfox protocol 129Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 81IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 46Neoadjuvant Therapy 45Standard of Care 44Magnetic Resonance Spectroscopy 43Biopsy 43Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 38Surveys and Questionnaires 38Cyclophosphamide 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × surufatinib × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Zhejiang University

Phase 2 Unknown
61 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡